HYPMED

The HYPMED consortium is made up of ten partner organiastions from Europe. The consortium includes major universities, research institutes, clinics as well as major industry and small-to-medium-sized enterprises... The HYPMED project is developing a hybrid system of two medical imaging modalities (MRI and PET) for improved diagnosis of breast cancer and personalised therapy control... Breast cancer is one of the leading causes of cancer death in women and a major socioeconomic issue throughout the world. With the detection methods available today, diagnosing breast cancer early enough is still not possible in many cases. As well as the problem of detection, there is an ever-increasing need for improved non-invasive characterisation of cancer. Targeted therapies require an in-depth analysis of cancer to select and guide appropriate treatment. Both, positron emission tomography (PET) and magnetic resonance imaging (MRI) can provide molecular and functional information that may be of..